216 related articles for article (PubMed ID: 35459558)
1. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
Braeye T; Catteau L; Brondeel R; van Loenhout JAF; Proesmans K; Cornelissen L; Van Oyen H; Stouten V; Hubin P; Billuart M; Djiena A; Mahieu R; Hammami N; Van Cauteren D; Wyndham-Thomas C
Vaccine; 2022 May; 40(22):3027-3037. PubMed ID: 35459558
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
Braeye T; Catteau L; Brondeel R; van Loenhout JAF; Proesmans K; Cornelissen L; Van Oyen H; Stouten V; Hubin P; Billuart M; Djiena A; Mahieu R; Hammami N; Van Cauteren D; Wyndham-Thomas C
Vaccine; 2023 May; 41(20):3292-3300. PubMed ID: 37085456
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
Zeng B; Gao L; Zhou Q; Yu K; Sun F
BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
[TBL] [Abstract][Full Text] [Related]
6. Covid-19 Vaccine Effectiveness in New York State.
Rosenberg ES; Dorabawila V; Easton D; Bauer UE; Kumar J; Hoen R; Hoefer D; Wu M; Lutterloh E; Conroy MB; Greene D; Zucker HA
N Engl J Med; 2022 Jan; 386(2):116-127. PubMed ID: 34942067
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
[TBL] [Abstract][Full Text] [Related]
8. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D
N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982
[TBL] [Abstract][Full Text] [Related]
10. Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study.
Homan T; Mazzilli S; Chieti A; Musa A; Roth A; Fortunato F; Bisceglia L; Prato R; Lopalco PL; Martinelli D
Sci Rep; 2022 Nov; 12(1):18597. PubMed ID: 36329239
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022.
Braeye T; van Loenhout JAF; Brondeel R; Stouten V; Hubin P; Billuart M; Chung PYJ; Vandromme M; Wyndham-Thomas C; Blot K; Catteau L
Euro Surveill; 2023 Jun; 28(26):. PubMed ID: 37382885
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
Bello-Chavolla OY; Antonio-Villa NE; Valdés-Ferrer SI; Fermín-Martínez CA; Fernández-Chirino L; Vargas-Vázquez A; Ramírez-García D; Mancilla-Galindo J; Kammar-García A; Ávila-Funes JA; Zúñiga-Gil CH; García-Grimshaw M; Ceballos-Liceaga SE; Carbajal-Sandoval G; Montes-González JA; Zaragoza-Jiménez CA; García-Rodríguez G; Cortés-Alcalá R; Reyes-Terán G; López-Gatell H; Gutiérrez-Robledo LM
Int J Infect Dis; 2023 Apr; 129():188-196. PubMed ID: 36775188
[TBL] [Abstract][Full Text] [Related]
15. Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern.
Lyngse FP; Mølbak K; Denwood M; Christiansen LE; Møller CH; Rasmussen M; Cohen AS; Stegger M; Fonager J; Sieber RN; Ellegaard KM; Nielsen C; Kirkeby CT
Nat Commun; 2022 Jun; 13(1):3764. PubMed ID: 35773247
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Moyano L; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F
Vaccine; 2023 Oct; 41(42):6291-6299. PubMed ID: 37679278
[TBL] [Abstract][Full Text] [Related]
18. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.
Kaplonek P; Deng Y; Shih-Lu Lee J; Zar HJ; Zavadska D; Johnson M; Lauffenburger DA; Goldblatt D; Alter G
Cell Rep Med; 2023 May; 4(5):101048. PubMed ID: 37182520
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
Lytras T; Kontopidou F; Lambrou A; Tsiodras S
J Med Virol; 2022 Oct; 94(10):5044-5050. PubMed ID: 35701379
[TBL] [Abstract][Full Text] [Related]
20. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
